Supplement

– Cost Effective Supplements

Bacopa monnieri

Quick navigation


What are Bacopa monnieri's other names?

  • Aindri
  • Graticola monnieri L.
  • Herpestis monniera L. Kunth.
  • Jalabrahmi
  • Lysimachia monnieri L. Cent.
  • Thyme-leafed gratiola
  • Water hyssop

What is Bacopa monnieri's recommended dosage?

  • Recommended daily intake: 300 mg

What supplements interact with Bacopa monnieri?

  • Bacopa monnieri and Ashwagandha

  • Bacopa monnieri and Curcumin

  • Bacopa monnieri and Fish Oil

  • Bacopa monnieri and Green Tea Extract

  • Bacopa monnieri and Milk Thistle

  • Bacopa monnieri and Guduchi


What can Bacopa monnieri help with?

  • Bacopa monnieri for Anxiety

  • Bacopa monnieri for Depression

  • Bacopa monnieri for Memory


What is Bacopa monnieri used for?

  • Bacopa monnieri for Mental health

test
Moderately Positive


Bacopa significantly improved memory acquisition and retention in healthy older Australians. This concurs with previous findings and traditional use. Bacopa caused GIT side-effects of increased stool frequency, abdominal cramps, and nausea.


test
Moderately Positive


SBME is efficacious in subjects with age-associated memory impairment.


test
Moderately Positive


The current study attempted to determine the chronic effects of single daily dose of 450 mg of Brahmi extract on cognitive performance and anxiety in healthy adults. The results of the current study are not in agreement with findings of some of the earlier studies which have found improvement both on cognitive parameters and a reduction of anxiety scores.


test
Moderately Positive


The current study provides support for the two other published studies reporting cognitive enhancing effects in healthy humans after a 90 day administration of the Bacopa monniera extract. Further studies are required to ascertain the effective dosage range, the time required to attain therapeutic levels and the effects over a longer term of administration.


test
Moderately Positive


The results show a significant effect of the Brahmi on a test for the retention of new information. Follow-up tests showed that the rate of learning was unaffected, suggesting that Brahmi decreases the rate of forgetting of newly acquired information. Tasks assessing attention, verbal and visual short-term memory and the retrieval of pre-experimental knowledge were unaffected. Questionnaire measures of everyday memory function and anxiety levels were also unaffected.


test
Moderately Positive


The study was a double-blind, placebo-controlled independent group design in which subjects were randomly allocated to one of two treatment conditions, Bacopa monniera (300 mg) (n = 18) or placebo (n = 20). Neuropsychological testing was conducted before and 2 h after drug administration. No significant changes were found on any of the tests. The findings suggest that Bacopa monniera, at least for the dose administered, has no acute effects on cognitive functioning in normal healthy subjects.


test
Moderately Positive


These findings suggest that B. monniera may improve higher order cognitive processes that are critically dependent on the input of information from our environment such as learning and memory.


test
Moderately Positive


This study provides further evidence that B. monnieri has potential for safely enhancing cognitive performance in the aging.


  • Bacopa monnieri for Emotional health


What are Bacopa monnieri's effects on the body?

  • Bacopa monnieri for the Nervous System

Bacopa significantly improved memory acquisition and retention in healthy older Australians. This concurs with previous findings and traditional use. Bacopa caused GIT side-effects of increased stool frequency, abdominal cramps, and nausea.


SBME is efficacious in subjects with age-associated memory impairment.


The current study attempted to determine the chronic effects of single daily dose of 450 mg of Brahmi extract on cognitive performance and anxiety in healthy adults. The results of the current study are not in agreement with findings of some of the earlier studies which have found improvement both on cognitive parameters and a reduction of anxiety scores.


The current study provides support for the two other published studies reporting cognitive enhancing effects in healthy humans after a 90 day administration of the Bacopa monniera extract. Further studies are required to ascertain the effective dosage range, the time required to attain therapeutic levels and the effects over a longer term of administration.


The results show a significant effect of the Brahmi on a test for the retention of new information. Follow-up tests showed that the rate of learning was unaffected, suggesting that Brahmi decreases the rate of forgetting of newly acquired information. Tasks assessing attention, verbal and visual short-term memory and the retrieval of pre-experimental knowledge were unaffected. Questionnaire measures of everyday memory function and anxiety levels were also unaffected.


The study was a double-blind, placebo-controlled independent group design in which subjects were randomly allocated to one of two treatment conditions, Bacopa monniera (300 mg) (n = 18) or placebo (n = 20). Neuropsychological testing was conducted before and 2 h after drug administration. No significant changes were found on any of the tests. The findings suggest that Bacopa monniera, at least for the dose administered, has no acute effects on cognitive functioning in normal healthy subjects.


These findings suggest that B. monniera may improve higher order cognitive processes that are critically dependent on the input of information from our environment such as learning and memory.


This study provides further evidence that B. monnieri has potential for safely enhancing cognitive performance in the aging.


Scroll to top